Meet Us at Upcoming Conferences

Integral Molecular is built on innovation and driven to impact the scientific community and human health. We apply deep expertise in target biology, antibody discovery, virology, and protein engineering to advance therapies against difficult-to-treat diseases.

Home » Company » News & Events » Fall 2025 Conferences

Where You Can Find Us

Pan-Reactive mAbs Enable Preclinical Animal Models: High-quality mAb reagents for hitting targets in diverse animal species

Up to One-Third of Antibody Drugs Are Nonspecific: A systematic evaluation of drugs throughout clinical and preclinical development

Developing a Comprehensive Proteome Array Assessing MAb Specificity: Testing binding interactions against >7,000 native membrane and secreted proteins

A New Approach Methodology (NAM) for Specificity Testing: ISTAND qualification of the Membrane Proteome Array to evaluate off-target binding of MAb-based therapies

GPRC5D Multispecific Antibodies Targeting Multiple Myeloma

Presentation: How Specific are Antibody Drugs? Revealing insights from a new generation of specificity assays

Presentation: Pan-Reactive MAbs for Membrane Proteins to Enable Pre-Clinical Development in Underutilized Mammalian Models

Short Course: SC2: Best Practices for Targeting GCPRs, Ion Channels, and Transporters with Monoclonal Antibodies

Poster: Pan-Reactive mAbs Enable Preclinical Animal Models: High-quality mAb reagents for hitting targets in diverse animal species

Poster: A New Approach Methodology (NAM) for Specificity Testing: ISTAND qualification of the Membrane Proteome Array to evaluate off-target binding of MAb-based therapies

Poster: CDR-Scanning for Antibody Engineering and Species Cross-Reactivity

American College of Toxicology, Phoenix, AZ, Nov 16-19
Advanced Therapies, Philadelphia, PA, Nov 18-20
Antibody Engineering and Therapeutics, San Diego, CA, Dec 14-17